The Motley Fool, founded in 1993 by brothers David and Tom Gardner, is a multimedia financial services company dedicated to empowering individual investors with accessible, actionable advice. Headquartered in Alexandria, Virginia, the company offers a range of products, including stock recommendations, investment research, and personal finance guidance, through its popular website, newsletters, podcasts, and premium subscription services.
Century Aluminum CEO Sells 150000 Shares as Aluminum Prices Soar This aluminum producer has been flourishing, and with the metal's price soaring, the company continues to benefit.
Prediction: 2 Things That Will Happen to Alibaba in 2026 Alibaba's e-commerce empire may no longer be the company's biggest growth story. Instead, artificial intelligence and cloud infrastructure are quickly taking center stage.
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.
Ralliant Director Purchases 2350 Shares as Institutional Investors Push for Stock Buyback After a rough Q4 FY 2025 earnings, Ralliant's stock has reached an all-time low. Yet, one of the company's board directors purchased insider shares after the underwhelming earnings.
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.
Vita Coco CFO Sells 4000 Shares as Stock Sets to Join S&P SmallCap 600 This global beverage company had a strong run in 2025, and now, its stock is set to join one of the top funds in the market.
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.
Why Scholastic Stock Climbed This Week The world's largest publisher of children's books is buying back a large swath of its shares.
Why This $18 Million Sale Might Signal a Shift as a China Tech Bet Falls 34% This China-based tech firm links employers and job seekers through its digital recruitment platform serving a broad labor market.
Is Apple Stock Going to $500? Here's What Has to Happen. After an impressive 953% trailing-10-year total return, investors are ready to tackle the next milestone.
Is Micron the Next Nvidia? Micron is experiencing similar sharp revenue growth to Nvidia during the early months following the launch of ChatGPT.
Reddit Stock is Crashing: Is This a Generational Buying Opportunity? Social media companies other than Meta Platforms are struggling to gain investor traction.
This Biotech Was Quietly Bought Before a $58 Per Share Takeout This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.
Why Is SoFi Stock Crashing, and Should You Buy the Dip? This financial technology stock is struggling to shift investor sentiment.
Is This Stock a Buy on the Dip? This company has a habit of beating the market over long periods.
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.
Bristow Group's CFO Just Sold $1.2 Million in Stock — But Is That the Whole Equation? Bristow Group, a global aviation services provider to offshore energy firms, reported a notable insider sale in its latest SEC filing.
Uber's Advertising Business May Be Bigger Than Investors Think Uber is best known for moving people and delivering food. However, something small but potentially profitable is growing at the company.
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.
This Nuclear Energy Trend Could Be Bigger Than Investors Think in 2026 Small modular reactors are shaping up to be one of the biggest trends in nuclear power and BWX Technologies is one of the best ways to play it.
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment.
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but it also means giving up some upside when risk appetite shifts toward early-stage biotech companies.
EV Stocks Have Massive Upside, but Investors Need to Avoid This Profit Blackhole While this young and intriguing EV stock has immense upside, it comes with too much risk for many investors -- here's why.
Brightlight Capital Cuts Hilton Grand Vacations Stake to $13.6 Million Hilton Grand Vacations depends on timeshare sales and financing, which renders its earnings sensitive to fluctuations in consumer demand and credit conditions. The extent to which recurring revenue can stabilize financial results is critical to the company’s long-term performance.
Harley-Davidson Executive Sells Over 4,000 Shares Harley-Davidson, a global motorcycle manufacturer, saw an insider sale amid a year of continued business and stock struggles.
3 Green Energy Stocks to Buy in March Here's how to participate as the world slowly shifts away from dirtier energy sources and toward cleaner ones.
Meta Stock Slips Below $600. Time to Buy? The social media giant's rapid revenue growth is impressive. But a heavy step-up in planned expenses is raising the stock's risk profile.
Palantir Is Executing Perfectly. History Says It Won't Be Enough. The historical record is brutal for S&P 500 companies valued like Palantir.
Here's Why Gemini Space Station Stock Slumped This Week The company's fourth quarter earnings were pretty much as expected, but Wall Street analysts are concerned by the company's future earnings prospects.
Fluor Is Expanding Its Nuclear Energy Projects in Europe. Is Now the Time to Buy? Fluor is one company that stands to benefit from the nuclear energy infrastructure build-out in the coming years.
Down 23% This Year, Is It Finally Time to Buy Snowflake Stock? Snowflake's already rapidly growing top line accelerated in fiscal Q4.
A Travel + Leisure Co. Insider Dumped Shares Worth $2.2 Million. Is the Stock a Buy or Sell? Travel + Leisure Co., a major player in vacation ownership, disclosed notable insider selling following a year of robust stock performance.
2 Great Dividend-Paying Oil Stocks to Buy as Oil Surges These oil stocks can grease the wheels of your passive income machine.
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch This clinical-stage biotech develops immunology therapies for autoimmune and inflammatory diseases, with a diverse pipeline underway.
The Best Stocks to Invest $5,000 in Right Now Nvidia and Alphabet are two top stocks to own right now.
Is IMAX Stock a Buy or Sell After a Director Dumped Shares Worth $21.5 Million? IMAX, a leader in cinematic technology and global theater systems, reported a notable insider sale amid strong one-year share performance.
Amazon Gave Up, but "The Wheel of Time" Gets a Second Chance What happens when Amazon walks away from a fantasy franchise? In this case, the "Arcane" producer steps in with an omnichannel production plan.
Goldman Sachs Projects $700 Billion in Artificial Intelligence (AI) Capex This Year. Here's My Top Stock to Buy. With massive amounts of cash going to AI, the biggest bottleneck could be solved by a company like Brookfield Renewable.
The Best Retirement States in the U.S. in 2026 The Motley Fool ranked all 50 states based on what retirees say actually matters. Here are the best.
Prediction: XRP Will Be Worth This Much in 5 Years, and the Math Might Surprise You If 14% of global cross-border payments run through the XRP blockchain, the price of XRP could skyrocket.
3 High-Yield Energy Stocks to Buy in March The soaring price of energy and geopolitical instability means energy stocks are an essential part of an investor's portfolio.
The Ultimate Growth Stock to Buy With $1,000 Right Now It won't come cheap, but little of what's truly worth owning ever is.
Got $1,000? This Under-the-Radar AI Stock Could Be a Future 10-Bagger Despite the recent pullback, I'm doubling down on Credo Technology. It's an overlooked but critical backbone of the AI ecosystem.
3 Ways the Strait of Hormuz Could Affect Coca-Cola (KO) In 2026 The world's largest beverage maker could face some near-term challenges.
Archer Aviation Is Well Below Its Production Targets. Here Are 3 Headwinds Facing the eVTOL Leader. Archer Aviation hasn't been talking about its production, which highlights a few key problems for the business.
3 Top EV Stocks With AI Upside to Buy Right Now Some electric vehicle stocks are evolving to become artificial intelligence stocks.
Massive News: Nvidia Just Made a $2 Billion Bet on Nebius Nvidia's $2 billion bet may have changed Nebius forever, but the real opportunity could hinge on one crucial piece investors still aren't fully pricing in.
Better Real Estate ETF: FlexShares' GQRE vs. State Street's RWR Explore how differing costs, yields, and global exposure set these two real estate ETFs apart for income and diversification seekers.
3 Possible Oil Price Scenarios For 2026 There are three oil scenarios; these are the businesses that could be affected in each one.
